智通财经APP讯，医脉通(02192)发布公告，根据本公司于2021年3月29日采纳的首次公开发售前购股权 计划向行使购股权的本公司一位董事于2026年3月4日发行30万股普通股。 根据本公司于2021年3月29日采纳的首次公开发售前购股权计划向行使购股权的本公司一位员工于2026 年3月4日发行2.5万股普通股。 ...

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 香港联交所最新数据显示，2月24日，FIL Limited增持医脉通（02192）271.55万股，每股作价9.6301港 元，总金额约为2615.05万港元。增持后最新持股数目约为3717.26万股，最新持股比例为5.04%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新数据显示，2月24日，FIL Limited增持医脉通（02192）271.55万股，每股作价9.6301港 元，总金额约为2615.05万港元。增持后最新持股数目约为3717.26万股，最新持股比例为5.04%。 责任编辑：卢昱君 客户端 ...

医脉通(02192)发布公告，根据本公司于2021年3月29日采纳的首次公开发售前购股权计划向行使购股权 的本公司一位董事于2026年2月27日发行20万股普通股。 ...

智通财经APP获悉，大华继显发布研报称，首次给予医脉通(02192)"买入"评级，目标价13.5港元，对应 2026年预测市盈率约24.1倍。该行指出，医脉通是中国领先的医师平台，用户覆盖全国88%的执业医 师，形成以医师为中心的B2B细分市场，可与聚焦消费者的同业形成互补，预料其轻资产及高利润率模 式支持2025至2027年收入及经调整净利润年均复合增长17%及15%，看好其净现金水平、高利润率前景 及介乎50%至60%潜在派息比率。 ...

Core Viewpoint - One of New Zealand's largest healthcare platforms has been hacked, resulting in the theft of personal health information of over 100,000 users [1] Group 1: Incident Details - The hacker has threatened to publicly release or sell the stolen data, demanding a ransom [1] - Approximately 120,000 users' personal health data was stolen from the private entity "Manage My Health" digital platform [1] - The breach affected a specific module within the system, rather than the entire system [1]

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of a total of 930,000 ordinary shares on January 5, 2026, as part of its pre-IPO share option plan adopted on March 29, 2021 [1] Group 1 - The company will issue 700,000 ordinary shares to two directors exercising their share options [1] - An additional 230,000 ordinary shares will be issued to one employee exercising their share options [1]

Core Viewpoint - The strategic partnership between Dingxiangyuan and JACC has successfully bridged the gap between Chinese clinicians and global cardiovascular research, enhancing academic collaboration and knowledge dissemination in the field [1][2][5]. Group 1: Achievements of the Partnership - Over the past year, Dingxiangyuan and JACC have collaborated under the vision of "More Health Better Life," focusing on academic exchanges, conference reporting, and empowering physicians [2]. - The launch of the "JACC x Dingxiangyuan" monthly publication has provided Chinese doctors with access to the latest research findings in an understandable format, serving as a vital resource for frontline medical professionals [2]. - The collaboration has led to significant initiatives such as the "Asia's Top Ten Research" announcement at the 2025 China International Cardiovascular Disease Conference, establishing a benchmark for cardiovascular research in Asia [2]. Group 2: Future Directions - The partnership aims to deepen collaboration in academic exchanges and conference reporting, particularly leveraging AI technology to enhance the integration of academic cooperation [6][8]. - Dingxiangyuan plans to utilize its advantages in AI technology and medical applications to further support JACC's academic outreach and influence in the Chinese market [6]. - The future collaboration will focus on making academic knowledge more accessible and engaging through innovative formats, such as the "Top Journal Scout" program, which transforms complex academic content into competitive challenges [3][6].

Group 1 - The company, 医脉通 (02192), announced the issuance of 534,500 ordinary shares to a director exercising stock options under the pre-IPO stock option plan adopted on March 29, 2021 [1]

Group 1 - The core point of the article is that Franklin Templeton has increased its stake in the company Medlinker (02192) by acquiring 1.6715 million shares at a price of HKD 14.5086 per share, totaling approximately HKD 24.2511 million [1] - After the acquisition, Franklin Templeton's total shareholding in Medlinker is now 37.3465 million shares, representing a 5.09% ownership stake [1]

Core Insights - The company reported better-than-expected performance for 1H25, with revenue of 312 million yuan (+28.2% YoY) and net profit attributable to shareholders of 166 million yuan (+4.3% YoY) [1][2] - The growth in revenue is attributed to a rapid increase in the number of collaborative projects [1] Financial Performance - Non-IFRS EBIT for 1H25 reached 72.69 million yuan (+36.4% YoY), with a corresponding profit margin of 23.3% (+1.4 percentage points YoY) [1][2] - The gross margin for 1H25 was reported at 59.0% (-1.6 percentage points YoY), influenced by increased costs associated with digital marketing projects for pharmaceutical clients [2] Revenue Breakdown - Revenue by business segment for 1H25: Precision Marketing and Enterprise Solutions at 292 million yuan (+29.6% YoY), Medical Knowledge Solutions at 9.195 million yuan (+9.2% YoY), and Intelligent Patient Management Solutions at 10.46 million yuan (+11.5% YoY) [1] - Revenue by region for 1H25: Domestic revenue at 304 million yuan (+28.0% YoY) and overseas revenue at 77.55 million yuan (+37.5% YoY) [1] Client Engagement - The number of clients covered by Precision Education and Enterprise Solutions increased to 191 (+20.9% YoY), with a total of 445 projects (+32.4% YoY) [1] - The average number of collaborative projects per enterprise increased to approximately 2.3 in 1H25, compared to 2.1 in 1H24 [1] Dividend Policy - The company plans to distribute a dividend of 0.1166 yuan per share, with a total dividend payout of 85.615 million yuan, representing a payout ratio of approximately 55% [2] Product Development - The company launched AI products such as MedSeeker, MedPaper, and MedAssister, aimed at assisting physicians in clinical decision-making and improving research efficiency [3] - A new content generation module for pharmaceutical clients was introduced, which can reduce labor costs by 50% while ensuring content professionalism and compliance [3] Valuation and Forecast - The company maintains its target price at 17.5 HKD, based on a 39x EV/EBIT valuation for 2025, with a current trading multiple of approximately 28x [3]